Biofrontera

Biofrontera OCF/Debt

The Operating Cash Flow to Debt Ratio of Biofrontera (B8FK.DE) as of Oct 30, 2026 is -702.88 %. In the previous year, Operating Cash Flow to Debt Ratio was -331.90 % — a change of 111.78% (lower).

OCF/Debt

-702.88 %

YoY

111.78%

Last updated:

Operating Cash Flow to Debt Ratio of Biofrontera is 2025 -702.88 % . Operating Cash Flow to Debt Ratio of Biofrontera was 2024 -331.90 % . It decreases by 111.78% lower compared to the previous year.

The Biofrontera OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2018
-98.58 EUR
Jan 1, 2019
-141.04 EUR
Jan 1, 2020
-11.93 EUR
Jan 1, 2021
922.39 EUR
Jan 1, 2022
-259.49 EUR
Jan 1, 2023
-167.13 EUR
Jan 1, 2024
-331.90 EUR
Jan 1, 2025
-702.88 EUR
The Biofrontera OCF/Debt history
YEAROCF/DebtYoY
-702.88 %+111.78%
-331.90 %+98.58%
-167.13 %-35.59%
-259.49 %-128.13%
922.39 %-7,829.78%
-11.93 %-91.54%
-141.04 %+43.07%
-98.58 %-5.88%
-104.74 %-62.20%
-277.13 %+244.29%
-80.49 %+21.83%
-66.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Operating Cash Flow to Debt Ratio of Biofrontera is -702.88 % in 2025.

Operating Cash Flow to Debt Ratio of Biofrontera changed from -331.90 % to -702.88 %, representing a 111.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Biofrontera since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Biofrontera with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Biofrontera

All Key Metrics — Biofrontera